Talphera (TLPH) Total Non-Current Liabilities (2010 - 2026)
Talphera (TLPH) posted Total Non-Current Liabilities of $10.7 million for Q2 2026, up 1.55% on a QoQ basis from $10.5 million in Q1 2026, and up 17.07% year-over-year from $9.1 million in Q2 2025.
Analysis
Talphera (TLPH) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Talphera has reported Total Non-Current Liabilities for 17 years, with the latest figure at $10.7 million in Q2 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 17.07% year-over-year to $10.7 million in Q2 2026; TTM through Jun 2026 was $10.7 million, a 17.07% increase from a year earlier, with the FY2025 full-year figure at $10.3 million, up 12.36% from the prior year.
- Total Non-Current Liabilities was $10.7 million for Q2 2026 at Talphera, up from $10.5 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $25.6 million in Q1 2022, with the low at $3.6 million in Q3 2023.
- Average Total Non-Current Liabilities over 5 years is $11.4 million, with a median of $9.8 million recorded in 2024.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities tumbled 82.08% in 2023, then surged 159.9% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $18.6 million in 2022, then tumbled by 75.71% to $4.5 million in 2023, then surged by 103.32% to $9.2 million in 2024, then grew by 12.36% to $10.3 million in 2025, then rose by 3.68% to $10.7 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $10.7 million (Q2 2026), $10.5 million (Q1 2026), and $10.3 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 81.11 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 36.04 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 5.92 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 7.74 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 40.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 3.92 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 12.42 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 378.37 Mn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - | 10.69 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10.69 Mn |
| Mar 31, 2026 | 10.52 Mn |
| Dec 31, 2025 | 10.31 Mn |
| Sep 30, 2025 | 9.71 Mn |
| Jun 30, 2025 | 9.13 Mn |
| Mar 31, 2025 | 8.52 Mn |
| Dec 31, 2024 | 9.17 Mn |
| Sep 30, 2024 | 9.29 Mn |
| Jun 30, 2024 | 9.80 Mn |
| Mar 31, 2024 | 9.66 Mn |
| Dec 31, 2023 | 4.51 Mn |
| Sep 30, 2023 | 3.57 Mn |
| Jun 30, 2023 | 4.22 Mn |
| Mar 31, 2023 | 10.26 Mn |
| Dec 31, 2022 | 18.58 Mn |
| Sep 30, 2022 | 19.94 Mn |
| Jun 30, 2022 | 22.14 Mn |
| Mar 31, 2022 | 25.63 Mn |
| Dec 31, 2021 | 28.50 Mn |
| Sep 30, 2021 | 29.30 Mn |